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Chronic pulmonary aspergilloses: 
do they exist?  
Le aspergillosi polmonari croniche: esistono?  
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In an editorial of this journal in 2006, Professor de
Marinis made a heartfelt appeal to Italian pulmo-
nologists to become more active and involved in
the field of lung tumors [1]; today we find ourselves
in the same situation regarding pulmonary mycoses
with, we fervently hope, more chance of success.
Recently, within the span of one month two emi-
nent clinicians as well as a biologist, expert in the
field of mycoses, contested the existence of chronic
pulmonary aspergilloses [2]; in the same period
four patients were admitted with this diagnosis to
the  Pulmonary Aspergillosis Outpatient Clinic of
Niguarda Hospital in Milan. Hence it is justified to
ask ourselves the question if these diseases exist or
not and, if the answer is yes, to enquire about their
incidence, diagnosis and the related therapy.
That pulmonary mycoses and – of particular interest
for pulmonologists – the aspergilloses exist has
been known since the ’50s and they have always
posed a problem at diagnostic and therapeutic 
level; but the problem mainly interested hematolo-
gists, mycologists and infectivologists, and not only
in Italy (in contrast to the lung cancer issue which is
a strictly Italian question). In particular, chronic pul-
monary aspergilloses – formerly known as ‘chronic
necrotizing aspergillosis’ - were well defined back
in the ’90s by G. A. Sarosi [3].
Pulmonary mycoses are diseases caused by micro-
scopic fungi that, according to the patient’s immu-
nity status – due to deficiencies at both local (e.g. of
mucociliary clearance) and general level (acute and
chronic diseases, assumption of immune suppres-
sors), can involve the respiratory system to a more
or less severe degree [4]. In Europe, in particular in
Italy,  Aspergillus and Candida are the fungi respon-
sible in absolute terms for the most number of infec-
tions, in contrast to other continents where other
fungi have a significant incidence. While the acute
forms caused by Candida and Aspergillus have been
well investigated and classified as to the therapy
and the pulmonologist is normally required only
from the diagnostic-instrumental point of view – to
perform the fibrobronchoscopy – the allergic (asth-
ma and allergic bronchopulmonary aspergillosis)
and chronic forms (chronic pulmonary aspergillo-
sis) should be the prerogative of the pulmonologist:
they are the specialists that normally visit these pa-
tients. But the role of the internal medicine special-
ist should also not be overlooked: they can en-
counter these diseases in the context of their work,
especially in hospital. 
But how significant is this problem for pulmonolo-
gists? According to a brief epidemiological survey
carried out at the Niguarda Hospital in Milan over
a period of 4 consecutive months in which 2,440
first-time patients referred for respiratory symptoms
of the lower airways were screened, 20 patients
were found affected by pulmonary aspergillosis
(chronic or allergic): approximately 0.82% [2]. In
contrast, according to anglosaxon authors, about
10% of patients affected by chronic respiratory dis-
eases have an underlying Aspergillus infection [3-5],
while data from the Lombardy Region (Dr. Bersani
at the “4th Workshop Focus on Aspergillosis: an
Update 2011”) show an average of 320 cases/year,
equivalent to 4/10,000 for the potential patients af-
fected by chronic pulmonary diseases. Further, the
same author observed that 40% of all diagnoses of
aspergillosis in the Lombardy Region had been
made in only 3 hospitals (Niguarda Hospital,
University Polyclinic of Milan and San Matteo of
Pavia) [6]. These data – although of an approximate
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and discordant nature – lead to three conclusions: 
- the pulmonary aspergilloses constitute a real and,
numerically speaking, far greater problem than
other rare diseases and should thus receive more
attention, both from pulmonologists in the first in-
stance, but also from internal medicine specialists
and infectivologists;
- their identification and diagnosis depends on how
sensitized physicians are to detect them;
- their incidence should be adequately evaluated
by a specific joint national epidemiological survey
involving AIMAR, AIPO and SIMeR.
In this issue of Multidisciplinary Respiratory
Medicine the article by Luo et al. [7] is particularly
to be appreciated, even if somewhat “rough” com-
pared to current articles written by expert western
mycologists. It is notable above all for its sincerity
and humility of thought: the authors posed the
question if pulmonary mycoses exist and what im-
portance they have. To answer the question, the
Chinese pulmonologists utilized the oldest method-
ology of “modern” medicine: anatomical patholo-
gy. They verified in retrospect – over a time span of
one decade – the histological specimens (from diag-
nostic or interventional surgery and needle biopsy)
and correlated these with clinical, radiological and
laboratory data. The importance of this approach
should be underscored: histological data reported
in the literature in the field are in fact rather modest
and sporadic. 
The pulmonologists from the University of Xiang Ya
verified that “in more than 76% of cases the diag-
nosis was made by the anatomopathologist” –
hence only at the act of biopsy – confirming the dif-
ficulty of making correct mycological diagnoses in
life through the common laboratory, radiological
and clinical means. Hence, late and occasional di-
agnoses. And they found, also in their continent, a
greater incidence of pulmonary aspergillosis among
mycoses as a whole – as in Europe – with a signifi-
cant percentage of cryptococcosis, in contrast to
Italy; while candidiasis was not evaluated because
it is not in general susceptible to surgery. 
This article is noteworthy for the fact that it was con-
ceived and written by pulmonologists, an excep-
tional event in the literature worldwide; the Chinese
pulmonologists have significantly affirmed their
presence also in this field: it is the first time that a
school of specialization in pulmonology, and not a
single individual, has entered this field, and it is
likely that their effort will “infect” other Chinese
pulmonologists.
All pulmonologists should imitate this example, i.e.
show interest in a disease that is rare, precisely be-
cause it is not well known and thus not recognized.
Difficulties of diagnosis certainly exist, because the
diagnosis is first suspected with clinical intelligence
and then confirmed with instrumental methods. But
at least the doubt should arise each time a chronic
pulmonary disease, even if correctly treated, does
not respond to the treatment: three simple examina-
tions can be of help, i.e. total IgE, RAST for
Aspergillus and anti-Aspergillus antibodies for im-
munodiffusion, as well as the Prick test. Positivity
on one of these tests should lead one to pose in dif-
ferential diagnosis an aspergillar disease. Recently
the use also of positron-emission tomography (PET)
has been proposed as an  important complementary
test: a positive finding may demonstrate, in the con-
text of areas considered fibrotic from the CT scan, ar-
eas of inflammation confirming the diagnosis in the
case of presence of anti-aspergillus antibodies, or of
cultural findings of Aspergillus spp. or justify the per-
formance of a  fine-needle aspiration biopsy [8].
From the therapeutic point of view, fortunately the
number of treatments available in Italy has expand-
ed, but so also unfortunately has the number of side
effects and in particular of pharmacologic interac-
tions, with the result that prescription of antiblastics
and immune suppressors has become more diffi-
cult: of voriconazole, in particular, and more re-
cently of posaconazole as well as echinocandin.
These diagnostic and therapeutic difficulties suggest
the need for a telematic network to be set up as a
reference point for specialized Centers and other fa-
cilities, as recommended at the recent congress on
aspergilloses: it is our hope that Italian pulmonolo-
gists will be able to create such a network.
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